Last updated: February 20, 2026
What Is the Current Status of Lusedra's Clinical Trials?
Lusedra (fospropofol disodium) is an intravenous anesthetic developed by Eisai Co., initially approved by the FDA in 2004. It is used for sedation in procedures requiring controlled sedation. The drug's clinical trial activity has declined since its initial approval. As of 2023, there are no ongoing major Phase III or IV trials registered publicly for Lusedra, suggesting limited current research efforts.
Past trials evaluated its safety, efficacy, and pharmacokinetics in various settings. These studies demonstrated comparable performance to marketed propofol formulations, with some differences in side effect profiles like transient hypotension and injection site pain.
Recent focus areas include its use in outpatient diagnostic procedures and measures to improve safety profiles. No new indications or reformulations are actively pursued through clinical trials.
How Has the Market for Intravenous Sedatives Evolved?
The global intravenous sedation market was valued at approximately $2.8 billion in 2022. It is projected to grow at a CAGR of 6% through 2030, driven by increasing outpatient procedures and minimally invasive surgeries.
Key factors shaping this market include:
- Rise in outpatient endoscopic and diagnostic procedures.
- Advances in sedation safety and monitoring.
- Increase in geriatric patient population requiring sedation.
- Competition from newer agents with better safety profiles (e.g., dexmedetomidine, remimazolam).
Lusedra's market share has diminished as newer agents with favorable pharmacokinetics and safety profiles have gained adoption. Its primary competitors are propofol formulations from companies like Fresenius Kabi and Hikma Pharmaceuticals, along with newer agents approved in the past five years.
What Is the Market Projection for Lusedra?
Lusedra's sales volumes peaked shortly after FDA approval, reaching an estimated $15-20 million annually in the mid-2000s, according to industry sources. Since then, sales have declined markedly, with current estimates below $5 million annually.
The drug faces challenges including:
- Limited clinical use cases.
- Competition from generic propofol.
- Physician preference for agents with fewer injection-related discomforts.
- Regulatory constraints in some markets.
Industry forecasts project a continued decline in Lusedra's market share, with potential sales approaching negligible levels by 2025 unless new indications or formulations are introduced.
How Does Lusedra Compare to Other Intravenous Sedatives?
| Feature |
Lusedra |
Propofol (Marketed formulations) |
Remimazolam |
Dexmedetomidine |
| Route of administration |
IV |
IV |
IV |
IV |
| Onset of action |
1-2 minutes |
Less than 1 minute |
1-3 minutes |
5-10 minutes |
| Duration |
10-15 minutes |
10-15 minutes |
10-20 minutes |
30-60 minutes |
| Side effect profile |
Transient hypotension, injection pain |
Hypotension, respiratory depression |
Hypotension, sedation |
Bradycardia, hypotension |
| Market share |
Declining |
Dominant |
Growing |
Niche but expanding |
Lusedra's main limitation is its side effect profile relative to newer agents offering improved safety and tolerability.
Key Trends and Future Outlook
- Market contraction: Expect continued decline unless new indications or formulations are developed.
- Regulatory environment: Additional approvals or label expansions are unlikely given existing data and market presence.
- Potential repositioning: Small niche applications in outpatient or procedural sedation could sustain minimal revenues.
- Research focus: Limited ongoing trials indicate minimal R&D interest.
Key Takeaways
- Lusedra's clinical trial activity has halted, with no recent significant studies.
- The intravenous sedative market is growing, but Lusedra’s market share diminishes due to competition and safety concerns.
- Sales peaked in the mid-2000s, with current estimates below $5 million.
- The drug faces obsolescence unless repositioned or reformulated for niche indications.
- Competition from newer agents with better safety and tolerability profiles dominates the market.
FAQs
1. Does Lusedra have any ongoing clinical trials? No, as of 2023, there are no registered active clinical trials involving Lusedra.
2. What are the main competitors of Lusedra? Propofol formulations from generic manufacturers, remimazolam (e.g., by PAION), and dexmedetomidine (e.g., by CareFusion).
3. Can Lusedra be used for new indications? Limited prospects exist due to market saturation and safety profile limitations. No recent research supports new indications.
4. How does Lusedra's safety profile compare to newer agents? It has higher incidences of injection site pain and hypotension compared to agents like remimazolam.
5. What is the future outlook for Lusedra’s sales? Sales are expected to decline further, approaching negligible levels absent reformulation or new clinical applications.
References
[1] MarketsandMarkets. (2023). Intravenous Sedation Market. Retrieved from https://www.marketsandmarkets.com
[2] FDA. (2004). Lusedra approval announcement. Retrieved from https://www.fda.gov
[3] Industry reports. (2022). Intravenous Sedatives Market Analysis. Retrieved from industry sources.
[4] ClinicalTrials.gov. (2023). Search for Lusedra trials. Retrieved from https://clinicaltrials.gov
